UBS Group’s PRA Health Sciences, Inc. PRAH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-201,839
| Closed | -$33.3M | – | 10815 |
|
|
2021
Q2 | $33.3M | Buy |
201,839
+26,439
| +15% | +$4.41M | 0.01% | 1092 |
|
|
2021
Q1 | $26.9M | Buy |
175,400
+142,480
| +433% | +$19.3M | 0.01% | 1237 |
|
|
2020
Q4 | $4.13M | Sell |
32,920
-25,306
| -43% | -$2.83M | ﹤0.01% | 2660 |
|
|
2020
Q3 | $5.91M | Buy |
58,226
+24,856
| +74% | +$2.53M | ﹤0.01% | 2044 |
|
|
2020
Q2 | $3.25M | Sell |
33,370
-85,938
| -72% | -$8M | ﹤0.01% | 2420 |
|
|
2020
Q1 | $9.91M | Buy |
119,308
+17,740
| +17% | +$1.73M | ﹤0.01% | 1418 |
|
|
2019
Q4 | $11.3M | Buy |
101,568
+35,000
| +53% | +$3.6M | ﹤0.01% | 1848 |
|
|
2019
Q3 | $6.61M | Buy |
66,568
+27,564
| +71% | +$2.74M | ﹤0.01% | 2126 |
|
|
2019
Q2 | $3.87M | Sell |
39,004
-24,898
| -39% | -$2.38M | ﹤0.01% | 2542 |
|
|
2019
Q1 | $7.05M | Buy |
63,902
+14,871
| +30% | +$1.55M | ﹤0.01% | 1943 |
|
|
2018
Q4 | $4.51M | Sell |
49,031
-22,342
| -31% | -$2.26M | ﹤0.01% | 2250 |
|
|
2018
Q3 | $7.87M | Buy |
71,373
+9,627
| +16% | +$1M | ﹤0.01% | 1971 |
|
|
2018
Q2 | $5.76M | Sell |
61,746
-16,733
| -21% | -$1.44M | ﹤0.01% | 2216 |
|
|
2018
Q1 | $6.51M | Sell |
78,479
-49,313
| -39% | -$4.38M | ﹤0.01% | 2074 |
|
|
2017
Q4 | $11.6M | Buy |
127,792
+43,040
| +51% | +$3.58M | ﹤0.01% | 1598 |
|
|
2017
Q3 | $6.46M | Buy |
84,752
+4,996
| +6% | +$378K | ﹤0.01% | 1972 |
|
|
2017
Q2 | $5.98M | Sell |
79,756
-33,248
| -29% | -$2.3M | ﹤0.01% | 1986 |
|
|
2017
Q1 | $7.37M | Buy |
113,004
+38,976
| +53% | +$2.3M | ﹤0.01% | 1748 |
|
|
2016
Q4 | $4.08M | Sell |
74,028
-4,781
| -6% | -$262K | ﹤0.01% | 2283 |
|
|
2016
Q3 | $4.45M | Sell |
78,809
-17,224
| -18% | -$845K | ﹤0.01% | 2122 |
|
|
2016
Q2 | $4.01M | Buy |
96,033
+45,397
| +90% | +$2.09M | ﹤0.01% | 2147 |
|
|
2016
Q1 | $2.17M | Buy |
50,636
+3,621
| +8% | +$153K | ﹤0.01% | 2600 |
|
|
2015
Q4 | $2.13M | Sell |
47,015
-12,547
| -21% | -$527K | ﹤0.01% | 2734 |
|
|
2015
Q3 | $2.31M | Sell |
59,562
-2,324
| -4% | -$93K | ﹤0.01% | 2609 |
|
|
2015
Q2 | $2.25M | Buy |
61,886
+11,199
| +22% | +$354K | ﹤0.01% | 2857 |
|
|
2015
Q1 | $1.46M | Sell |
50,687
-5,432
| -10% | -$152K | ﹤0.01% | 3217 |
|
|
2014
Q4 | $1.36M | Buy |
+56,119
| New | +$1.26M | ﹤0.01% | 3308 |
|
Other funds holding PRAH
UBS Group's PRAH Position: Q3 2021 in Review
UBS Group sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 201,839 shares — an estimated $33.3M sold.
UBS Group first reported a position in PRAH in Q4 2014 and held it in 27 quarters. The position peaked at $33.3M in Q2 2021. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.
- UBS Group reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
- UBS Group sold 201,839 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $33.3M.
- UBS Group first reported a position in PRA Health Sciences, Inc. in Q4 2014 and held it in 27 quarters.
- UBS Group's PRA Health Sciences, Inc. position peaked at $33.3M in Q2 2021.
- 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.
Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.